gms | German Medical Science

26. Jahrestagung der Deutschen Retinologischen Gesellschaft

Deutsche Gesellschaft für Retinologie

27.09.2013, Hamburg

Treatment of wAMD patients with VEGF inhibitors: Insights from the routine clinical practice in Germany – the PONS Study

Meeting Abstract

  • Hansjürgen Agostini - Freiburg, Germany
  • S. Mueller - Institut für Pharmakoökonomie und Arzneimittellogistik, Wismar, Germany; Freiburg, Germany
  • C. Ehlken - Freiburg, Germany
  • U. Bauer-Steinhusen - Bayer Vital GmbH, Leverkusen, Germany
  • Z. Hasanbasic - Bayer Vital GmbH, Leverkusen, Germany
  • T. Wilke - Institut für Pharmakoökonomie und Arzneimittellogistik, Wismar, Germany

Retinologische Gesellschaft. 26. Jahrestagung der Retinologischen Gesellschaft. Hamburg, 27.-27.09.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13rg17

doi: 10.3205/13rg17, urn:nbn:de:0183-13rg177

Veröffentlicht: 20. August 2013

© 2013 Agostini et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Background: In Germany neovascular AMD is the leading cause for severe visual impairment. In 2/3 of patients visual acuity can be maintained by intravitreal injection of VEGF inhibitors. Based on clinical studies at least 7–8 injections are required in the first year. The PONS study is evaluating the management of wAMD patients receiving anti-VEGF therapy in routine clinical practice both from the physicians and patients perspective.

Methods: wAMD patients receiving anti-VEGF therapy were recruited into a cohort study in university and office based centers. Clinical documentation is performed retrospectively (max. 24 months) and prospectively (max. 12 months). In parallel patients are interviewed during structured telephone calls concerning their treatment condition.

Results: 480 patients were recruited by 23 participating centers (61.9% female; Ø 77.2 years). So far retrospective clinical data of 360 patients with variable duration of the anti-VEGF treatment are available (20.3% started treatment <3 months, 25.3% started treatment ≥3 months up to 12 months, 54.4% started treatment >12 months). The mean duration of treatment was 1.65 years. To date 404 patients were interviewed by telephone (61.4% female, Ø 77.0 years). 62.7% reported difficulties in organizing their travel and company for their scheduled visits, mainly due to the need for support from relatives (as stated by 58.3%).

Conclusions: Injection frequencies observed in routine clinical practice will be analyzed in comparison to data from clinical studies. Analysis of potential differences and identification of causes for deficits in patient care are in scope of the ongoing PONS study.